Controlling Hypertension in Primary Care: Hitting a moving target?

Size: px
Start display at page:

Download "Controlling Hypertension in Primary Care: Hitting a moving target?"

Transcription

1 Controlling Hypertension in Primary Care: Hitting a moving target? David J. Hyman, MD,MPH Professor of Medicine and Family & Community Medicine Chief, Section General Medicine Baylor College of Medicine No Conflicts of Interest

2 Controlling Hypertension in Primary Care: Hitting a moving target? Objectives Review why hypertension is the most important topic in medicine and the great job that primary care is doing Be familiar with the shifting and conflicting guidelines: JNC 7, JNC 8 now AHA/ACC 2017 vs AAFP/ACP 2017 vs. other international groups vs NCQA (clinical quality) metrics Appreciate the critical role of how the blood pressure is measured in interpreting the guidelines Be relieved by the lack of controversy in drug regimens Recognize and intervene on resistant hypertension

3 Hypertension is the most important topic in medicine.

4 Prevalence of Hypertension in the United States* 100% Hypertension Prevalence 80% 60% 40% 20% 6% 16% 31% 48% 65% 78% 0% Age *Based on NHANES data. Hypertension is defined as blood pressure 140/90 mmhg or antihypertensive treatment. Low reliability due to large relative error. Fields et al. Hypertension. 2004:44;

5 Benefits of Lowering BP Average Percent Reduction Stroke incidence 35 40% Myocardial infarction 20 25% Heart failure 50%

6 Global Disability Adjusted Life Years (DAYLs) Attributable to the 25 Leading Risk Factors 2010 Risk Factor 2010 Rank DALYs (95% UI) in thousands High blood pressure 1 173,556 ( Tobacco smoking, including exposure to secondhand smoke 2 156,838 (136, ) Household air pollution from solid fuels 3 108,084 (84, ,983) Diet low in fruit 4 104,095 (81, ,169) Alcohol use 5 97,237 (87, ) High body-mass index 6 93,609 (77, ,600) High fasting plasma glucose level 7 89,012 (77, ,390) Childhood underweight 8 77,316 (64,497-91,943) Expo sure to amblent particulate-matter pollution 9 76,163 (68,086-85,171) Physical inactivity or low level of activity 10 69,318 (58,646-80,182) Murray, Christopher J, et. al, New England Journal of Medicine, 2013

7 Diabetes: Tight Glucose vs Tight BP Control and CV Outcomes in UKPDS % Reduction In Relative Risk Stroke 5% 44% * Any Diabetic Endpoint 12% 24% * DM Deaths 10% Tight Glucose Control (Goal <6.0 mmol/l or 108 mg/dl) 32% Microvascular Complications 32% *P <0.05 compared to tight glucose control * 37% * Tight BP Control (Average 144/82 mmhg) Bakris GL, et al. Am J Kidney Dis. 2000;36(3): Reprinted by permission, Harcourt Inc.

8 Hypertension Control Horrible-Isn t it? Less than ½ of persons with hypertension are controlled 70% of people who start BP drugs stop within 5 years..

9 Blood Pressure Control Over Time Chobanian, N Engl J Med 2009;361:

10 The percentages are shown (mean and 95% confidence intervals) for hypertension prevalence, awareness, treatment, control, and proportion of treated patients controlled (control/treated) among adults 18 years of age in NHANES 1999 to 2012 at 2-year increments. Egan B M et al. Circulation. 2014;130: Copyright American Heart Association, Inc. All rights reserved.

11 Another database showing Hypertensives are mostly adherent 625,000 patients with prescription refill records available from insurer Adherent (>80%) 74.6% Moderate (60-79%) 15.3% Poor (<60%) 9.9% Pittman DG, et al Am J Managed Care 2010

12 Harris Health October 2018

13 Controlling Hypertension in Primary Care: Hitting a moving target? - Be familiar with the shifting and conflicting guidelines: JNC 7, JNC 8 now AHA/ACC 2017 vs AAFP/ACP 2017 vs. other international groups vs NCQA (clinical quality) metrics

14

15 Hypertension Treatment Effect Mirrors Observational Data Incidence of cardiovascular disease Systolic blood pressure (mmhg)

16 National Heart, Lung, and Blood Institute National High Blood Pressure Education Program U.S. Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

17 JNC BP Classifications: DBP Stage 4 DBP (mm Hg) Hypertensive Consider therapy Severe Severe Severe Moderate Moderate Moderate Mild Mild Mild Stage 3 Stage 3 Stage 2 Stage 2 Stage 1 Stage 1 Stage 2 Stage Normal Normal Normal Normal Optimal Optimal Highnormal Highnormal Highnormal Highnormal Prehypertension Normal JNC I JNC II JNC III JNC IV JNC V JNC VI JNC 7 JNC I. JAMA. 1977;237: JNC II. Arch Intern Med. 1980;140: JNC III. Arch Intern Med. 1984;144: JNC IV. Arch Intern Med. 1988;148: JNC V. Arch Intern Med. 1993;153: JNC VI. Arch Intern Med. 1997;157: Chobanian AV et al. JAMA. 2003;289:

18 Hypertension. 1999;34:

19 JNC BP Classifications: SBP SBP (mm Hg) No recommendations for SBP in JNC I or JNC II ISH Border - line ISH Border - line Normal Stage 2 Stage 1 Stage 4 Stage 3 Stage 3 Stage 2 Stage 2 Stage 1 Stage 1 Highnormal Highnormal Normal Normal Optimal Optimal Prehypertension Normal JNC I JNC II JNC III JNC IV JNC V JNC VI JNC 7 JNC I. JAMA. 1977;237: JNC II. Arch Intern Med. 1980;140: JNC III. Arch Intern Med. 1984;144: JNC IV. Arch Intern Med. 1988;148: JNC V. Arch Intern Med. 1993;153: JNC VI. Arch Intern Med. 1997;157: Chobanian AV et al. JAMA. 2003;289:

20 Goals of Therapy JNC 8 majority report: over age 60: DM, cad, Ckd 150/90 mm/hg 140/90 mm/hg JNC 8 minority report: over age 60: 140/90 mm/hg

21 2010 Accord BP Diabetics 120mmHg vs. 140mmHg Negative 2013 SPS3 Post subcortical <130 mmhg vs < 140 mmhg Negative stroke 2015 SPRINT high risk 120mmHG vs. 140mmHG Stopped early!! not DM or CVA Benefit

22 Sprint Trial Major inclusion criteria Age > 50 SBP (tx or un tx) At least one of : Clinical CVD except CVA CKD egfr Framingham 10yr CVD risk > 15% Age >75 Major exclusion criteria Stroke DM CHF(sx or EF<35%) proteinuria >1 g/d CKD egfr <20 ADHERENCE CONCERNS SBP achieved: mmhg NNT event 61 NNT to Prevent one death 90

23 AHA/ACC 2017 vs everyone else

24 AHA 2017

25 Changes in BP Categories from JNC 7 to the 2017 ACC/AHA HTN Guideline SBP DBP JNC ACC/AHA <120 and <80 Normal BP Normal BP and <80 Prehypertension Elevated BP or Prehypertension Stage 1 hypertension or Stage 1 hypertension Stage 2 hypertension 160 or 100 Stage 2 hypertension Stage 2 hypertension The 2017 ACC/AHA guideline definition of hypertension: SBP 130 mm Hg or DBP 80 mm Hg

26

27

28

29 If same patient was 60WF 10 yr risk 4.8% If 40 WM 10 yr risk 1.8% If 40 BM 10 yr risk 10.0% If 60 WM,BM,BF 10 yr risk >10% You have to use the calculator, guesstimates difficult

30 Prevalence of Hypertension 2017 ACC/AHA and JNC 7 Guidelines Prevalence of hypertension, % Number of US adults with hypertension, millions 13.7% 31.1, M Muntner et. al., Journal of the American College of Cardiology 2017, Nov 6 Muntner, et. al., Circulation 2017 Nov 13

31 JNC 8 AHA/ACC 2017 ESC/ESH 2018 ACP/AAFP 2017 Threshold for starting by age >60 150/90 < /90 all ages 140/90 130/80 High risk < /90 >80 160/90 >60 150/no rec strong >60 CVA/TIA consider 140 (weak) >60 high risk consider 140 (weak Target for on treatment BP >60 150/90 <60 140/90 <130/ to 130 but not <120 > >60 < 150 >60 CVA/TIA consider 140mmHG (weak) >60 High risk consider 140 mmhg (weak)

32 Hitting the target How do you measure the BP you are acting on?

33 BP Measurement Techniques Method In-office Brief Description Two readings, 5 minutes apart, sitting in chair. Confirm elevated reading in contralateral arm. Ambulatory BP monitoring Indicated for evaluation of white-coat HTN. Absence of 10 20% BP decrease during sleep may indicate increased CVD risk. Self-measurement In Office automated unobserved May help improve adherence to therapy and evaluate white-coat HTN. Pt alone in room

34 If mean office visit SBP 140mmHG control about 50% frequency 68% 95% 99.7% mean Number of standard deviations either side of mean

35 AHA 2017

36 Sprint Maybe much ado about nothing? 1) Sprint used unobserved Automated Office BP (AOBP) - pt seated alone in room for 5 minutes - only after 5 minutes of rest, would take 3 measurement 1 minute apart unobserved AOBP averages SBP 16mmHG lower than regular office BP often similar to day ABPM 2) Intervention achieved SBP mmhg = about current 140 3) Control group had target of 140mmHG, could have baseline medications reduced to get there actual SBP controls mmhg = if individual at 140, = 166 Kjeldsen & Mancia European Heart J 2016

37 What BPs are we being graded on?

38 Definition of Hypertension Control in Clinical Practice NCQA/ HEDIS Enrolled for 1 year or more Have a hypertension code in 1st 6 months of year Age BP at last visit in chart used Control: < 140 and < 90 mmhg at sampled visit Sennett C, Managed Care 2000

39 NCQA HEDIS 2019 < 140/90 on last visit in evaluation period or remote BP devices electronically submitted HEDIS / w dm 140/ w/o dm 150/90

40 BP Drugs now the easy part - It will likely take more than one drug, tell patients this right from start - If it is really high start 2 drugs - Multidrug combination pills maybe good - If the blood pressure is high on subsequent visits- titrate the medication!!!! Clinical Inertia: not lack of access or non-adherence is biggest reason for lack of control

41 Order of BP medication use: 1 st (Ace or ARB) or CCB or Diuretic For DM (Ace or ARB ) For African Origin no DM: CCB or Diuretic 2 nd (Ace or ARB) and CCB or (ACE or ARB) and Diuretic 3 rd (Ace or ARB) and CCB and Diuretic 4 th spironolactone Only then, the other classes Sometimes other classes needed for other conditions or contraindications

42 NO ENALAPRIL Use Lisinopril Few B blockers NO Atenolol The REAL Dose of HCTZ is 50mg Chlorthalidone may be coming to Harris Health

43

44 What if the patient s Blood Pressure does not respond? RESISTANT HYPERTENSION

45 Definitions Resistant Hypertension: office blood pressure that remains elevated despite optimal doses of 3 classes of medication including diuretic if tolerated or controlled on 4 medicines Pseudo-resistant Hypertension: seems to meet definition but on further evaluation pt is -Non-adherent - Controlled on 24 hour ABPM - not really on optimal medications, - only uncontrolled on poor office measurement True resistant: not pseudo- resistant Apparent Resistant Hypertension: seems to meet definition but pseudo-resistant not ruled out

46 Apparent Resistant Hypertension Drilling down on the medical regimen: Source Result Persell NHANES Any diuretic 86% 2011 Study BP, drug names loop 30% not dosage thiazide like 59%(HCTZ 93%) 539 patients uncontrolled > 3 aldo antagonists 3.0% or controlled > 4 drugs Hanselin Drug insurance data base Any diuretic 93% 2011 drug names, dose, No BPs loop 19% 140,000/5million hypertensives on thiazide like 80% (HCTZ 94%) > 4 drugs Chlorthalidone 3%, aldo antagonist 5.9% HCTZ mean dose 21.1 mg Fontil National Ambulatory Medical Care Survey Any diuretic 77% drug names, no dosages, office BP loop 23 % 1567 pts w uncontrolled > 3 or controlled thiazide like 56% (HCTZ 96%) > 4 drugs Chlorthalidone 1.2% aldo antagonists 3.9% Grigoryan Primary care patients uncontrolled Any Diuretic 91% 2013 > 3 drugs, n=34 loop 15% Drug names, doses, ABPM, thiazide like 84% (HCTZ electronic adherence monitor Chlorthalidone 0% aldo antagonists 0% > ½ max dose ace/arb/ccb HCTZ 24/26 at 25mg QD

47 Resistant Hypertension Uncommon if Appropriate Drugs used In a network of 200 practices across the Southeast with 468,000 treated hypertensives those uncontrolled on 3 or more drugs at acceptable dose: 4.7% Egan B, Zhao Y, Li J et al

48 Houston TX On a very detailed drill down using ABPM and electronic bottle cap monitoring: of Apparent resistant hypertenvsives (N=69) 22% normal ABPM 29% non adherent Essentially no one optimally treated, mostly HCTZ 25,no Chlorthalidone, no spironolactone Grigoryan L, Pavlik VN, Hyman DJ J Am Soc Hypertens 2013

49 Patients with severe BP elevations referred to resistant hypertension clinics or for device therapy have very high levels of non-adherence when measured by blood or urine samples

50 Diuretics are the key to controlling difficult to control hypertension The dose of HCTZ is 50mg!!!!!! Chlorthalidone if you can get it- 25 mg Spironolactone 25 to 50 mg is 4 th drug Eplerenone is alternative

51 What is real prevalence of resistant hypertension? A network of 200 practices across the Southeast 468,000 treated hypertensives - uncontrolled on 3 or more drugs at acceptable dose Semi Apparent Resistant Hypertension 4.7% Egan B, Zhao Y, Li J et al

52 Diuretics are the key to controlling difficult to control hypertension The dose of HCTZ is 50mg!!!!!! Chlorthalidone if you can get it- 25 mg Spironolactone 25 to 50 mg is 4 th drug Eplerenone is alternative

53 Conclusions Hypertension is the most important topic in Medicine! You don t have to accept the 2017 AHA/ACC guideline A well measured in office 140/90 is good criteria for starting 130/80 maybe indicated is some high risk patients 130/80 maybe reasonable target if well tolerated It is very fair that we will still be graded on 140/90 If someone actually fits SPRINT criteria, and wants to do it- go for it! but remember it is an average SBP 121mm, not always less than 120mmHG

54 Conclusions continued.. Measurement counts- follow the literature -follow your office practicethe closer to Automated Office BP method the better Do drugs! ACE(ARB) CCB diuretics Hctz 50 aldactone 4 th Resistant hypertension: check adherence. Rare referral for 2 nd hypertension

55 Hypertension is the most important topic in medicine!!! Please do not let any differences in guidelines lead us to nihilism and inaction!!!

56

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine

More information

HYPERTENSION: ARE WE GOING TOO LOW?

HYPERTENSION: ARE WE GOING TOO LOW? HYPERTENSION: ARE WE GOING TOO LOW? George L. Bakris, M.D.,F.A.S.N.,F.A.S.H., F.A.H.A. Professor of Medicine Director, ASH Comprehensive Hypertension Center University of Chicago Medicine Chicago, IL USA

More information

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University

More information

MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk

MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu

More information

ADVANCES IN MANAGEMENT OF HYPERTENSION

ADVANCES IN MANAGEMENT OF HYPERTENSION Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%

More information

2/11/2019 CLINICAL IMPLEMENTATION OF THE UPDATED BP GUIDELINES DUALITY OF INTEREST

2/11/2019 CLINICAL IMPLEMENTATION OF THE UPDATED BP GUIDELINES DUALITY OF INTEREST CLINICAL IMPLEMENTATION OF THE UPDATED BP GUIDELINES George L. Bakris, M.D.,F.A.S.N., F.A.H.A. Professor of Medicine Director, Am Heart Assoc. Comprehensive Hypertension Center University of Chicago Medicine

More information

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered

More information

Hypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA

Hypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA Hypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA Case 1 What should be your BP goal for an elderly (> 75 yrs of

More information

Preventing and Treating High Blood Pressure

Preventing and Treating High Blood Pressure Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure

More information

Modern Management of Hypertension

Modern Management of Hypertension Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence

More information

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant

More information

Difficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair

Difficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair Difficult-to-Control & Resistant Hypertension Anthony Viera, MD, MPH, FAHA Professor and Chair Objectives Define resistant hypertension Discuss evaluation strategy for patient with HTN that appears difficult

More information

Managing Hypertension in 2016

Managing Hypertension in 2016 Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu

More information

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose. JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I

More information

Hypertension and Cardiovascular Disease

Hypertension and Cardiovascular Disease Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,

More information

None. Disclosure: Relationships with Industry Conflicts of Interests. Learning Objectives: Participants will be able to:

None. Disclosure: Relationships with Industry Conflicts of Interests. Learning Objectives: Participants will be able to: 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) James W. Shaw, MD Memorial Lecture

More information

Update on Current Trends in Hypertension Management

Update on Current Trends in Hypertension Management Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student

More information

Modern Management of Hypertension: Where Do We Draw the Line?

Modern Management of Hypertension: Where Do We Draw the Line? Modern Management of Hypertension: Where Do We Draw the Line? Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Blood Pressure

More information

ADVANCES IN MANAGEMENT OF HYPERTENSION

ADVANCES IN MANAGEMENT OF HYPERTENSION Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,

More information

The Latest Generation of Clinical

The Latest Generation of Clinical The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform

More information

Hypertension Management Controversies in the Elderly Patient

Hypertension Management Controversies in the Elderly Patient Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No

More information

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS? HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL

More information

T. Suithichaiyakul Cardiomed Chula

T. Suithichaiyakul Cardiomed Chula T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial

More information

Objectives. JNC 7 Is Nice But What s Up With JNC 8? Why Do We Care? Hypertension Background: Prevalence

Objectives. JNC 7 Is Nice But What s Up With JNC 8? Why Do We Care? Hypertension Background: Prevalence JNC 7 Is Nice But What s Up With JNC 8? 37 th Annual CAPA Conference October 4 th 2013 Ignacio de Artola, Jr. M.D. Assistant Professor of Clinical Family Medicine Medical Director, Primary Care Physician

More information

Hypertension: 2016 Clinical Update

Hypertension: 2016 Clinical Update PHASE Safety Net Community Benefit Hypertension: 2016 Clinical Update Presented by: Joseph Young, MD Hypertension Clinical Lead Kaiser Permanente Northern California October 6, 2016 Dr. Joseph Young Hypertension

More information

What s In the New Hypertension Guidelines?

What s In the New Hypertension Guidelines? American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the

More information

HYPERTENSION: UPDATE 2018

HYPERTENSION: UPDATE 2018 HYPERTENSION: UPDATE 2018 From the Cardiologist point of view Richard C Padgett, MD I have no disclosures HYPERTENSION ALWAYS THE ELEPHANT IN THE EXAM ROOM BUT SOMETIMES IT CHARGES HTN IN US ~78 million

More information

Jared Moore, MD, FACP

Jared Moore, MD, FACP Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner

More information

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of

More information

Update in Cardiology Pharmacologic Management of Cardiovascular Risk. Christopher C. Roe, MSN, ACNP

Update in Cardiology Pharmacologic Management of Cardiovascular Risk. Christopher C. Roe, MSN, ACNP Update in Cardiology Pharmacologic Management of Cardiovascular Risk Christopher C. Roe, MSN, ACNP Objectives 1. Verbalize understanding of new pharmacologic guidelines in the treatment of hypertension

More information

PHASE Preventing Heart Attacks & Strokes Everyday

PHASE Preventing Heart Attacks & Strokes Everyday PHASE Preventing Heart Attacks & Strokes Everyday Welcome to the PHASE Learning Community! Joseph D. Young, MD Kaiser Permanente Northern California Jean Nudelman Kaiser Permanente Northern California

More information

Objectives. Describe results and implications of recent landmark hypertension trials

Objectives. Describe results and implications of recent landmark hypertension trials Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships

More information

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977

More information

Combination Therapy for Hypertension

Combination Therapy for Hypertension Combination Therapy for Hypertension Se-Joong Rim, MD Cardiology Division, Yonsei University College of Medicine, Seoul, Korea Goals of Therapy Reduce CVD and renal morbidity and mortality. Treat to BP

More information

Challenges in Hypertension: Incorporating Evolving Clinical Data Into Practice

Challenges in Hypertension: Incorporating Evolving Clinical Data Into Practice Challenges in Hypertension: Incorporating Evolving Clinical Data Into Practice Faculty Jan Basile, MD Professor of Medicine Seinsheimer Cardiovascular Health Program Division of General Internal Medicine

More information

Managing Hypertension in 2018

Managing Hypertension in 2018 MANAGING HYPERTENSION IN 2018 How Do We Work With Conflicting Data and Conflicting Guidelines? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School

More information

RESISTANT HYPERTENSION

RESISTANT HYPERTENSION RESISTANT HYPERTENSION John D. Bisognano, MD PhD Professor of Medicine / Cardiology President-Elect, American Society of Hypertension Director, Outpatient Cardiology University of Rochester RESISTANT HYPERTENSION

More information

Hypertension Guidelines: Lessons for Primary Care. Paul A James MD Professor and Chair Department of Family Medicine University of Washington

Hypertension Guidelines: Lessons for Primary Care. Paul A James MD Professor and Chair Department of Family Medicine University of Washington Hypertension Guidelines: Lessons for Primary Care Paul A James MD Professor and Chair Department of Family Medicine University of Washington Disclaimer and Financial Disclosure I have no financial interests

More information

MANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION

MANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals

More information

Treating Hypertension in 2018: What Makes the Most Sense Today?

Treating Hypertension in 2018: What Makes the Most Sense Today? Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or

More information

Hypertension and the SPRINT Trial: Is Lower Better

Hypertension and the SPRINT Trial: Is Lower Better Hypertension and the SPRINT Trial: Is Lower Better 8th Annual Orange County Symposium on Cardiovascular Disease Prevention Saturday, October 8, 2016 Keith C. Norris, MD, PhD, FASN Professor of Medicine,

More information

Update in Hypertension

Update in Hypertension Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded

More information

Evaluation and Management of Hypertension in Women. Vesna D. Garovic, M.D. Moscow, Russia, December 2016

Evaluation and Management of Hypertension in Women. Vesna D. Garovic, M.D. Moscow, Russia, December 2016 Evaluation and Management of Hypertension in Women Vesna D. Garovic, M.D. Moscow, Russia, December 2016 2016 MFMER 3508058-1 Women are not small men There is nothing as powerful as an idea whose time has

More information

Hypertension 2015: Recent Evidence that Will Change Your Practice

Hypertension 2015: Recent Evidence that Will Change Your Practice Hypertension 2015: Recent Evidence that Will Change Your Practice Gerald W. Smetana, M.D. Division of General Medicine Beth Israel Deaconess Medical Center Professor of Medicine Harvard Medical School

More information

Στόχοι αρτηριακής πίεσης σε ειδικούς πληθυσµούς και επιλογή φαρµάκων

Στόχοι αρτηριακής πίεσης σε ειδικούς πληθυσµούς και επιλογή φαρµάκων Στόχοι αρτηριακής πίεσης σε ειδικούς πληθυσµούς και επιλογή φαρµάκων Εύα Καρπάνου Δ/ντρια Αντιυπερτασικού Ιατρείου Α ΚΚ Ωνάσειου ΚΚ Θεσσαλονίκη, 14/2/13 Η µελέτη δεν υποστηρίχθηκε από φαρµακευτικές εταιρείες

More information

Hypertension Update 2009

Hypertension Update 2009 Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin

More information

Best Practices in Cardiac Care: Getting with the Guidelines

Best Practices in Cardiac Care: Getting with the Guidelines Best Practices in Cardiac Care: Getting with the Guidelines December 9, 2014 Agenda Cardiovascular Disease: How do the guidelines fit into an implementation scheme? What the guidelines set out to accomplish

More information

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation

More information

We are delighted to have Dr. Roetzheim with us today to discuss Managing Hypertension in Older Adult Patients.

We are delighted to have Dr. Roetzheim with us today to discuss Managing Hypertension in Older Adult Patients. Richard Roetzheim, MD, MSPH is Professor and Chair, Department of Family Medicine at the University of South Florida Morsani College of Medicine. Dr. Roetzheim has considerable experience leading NIH funded

More information

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial

More information

Hypertension Putting the Guidelines into Practice

Hypertension Putting the Guidelines into Practice Hypertension 2017 Putting the Guidelines into Practice Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or

More information

DEPARTMENT OF GENERAL MEDICINE WELCOMES

DEPARTMENT OF GENERAL MEDICINE WELCOMES DEPARTMENT OF GENERAL MEDICINE WELCOMES 1 Dr.Mohamed Omar Shariff, 2 nd Year Post Graduate, Department of General Medicine. DR.B.R.Ambedkar Medical College & Hospital. 2 INTRODUCTION Leading cause of global

More information

Hypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)

Hypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B) Practice Guidelines and Principles: Guidelines and principles are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines and principles should be followed

More information

OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA

OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition ACOFP - The Heart of the Matter - An Evidence

More information

Reframe the Paradigm of Hypertension treatment Focus on Diabetes

Reframe the Paradigm of Hypertension treatment Focus on Diabetes Reframe the Paradigm of Hypertension treatment Focus on Diabetes Paola Atallah, MD Lecturer of Clinical Medicine SGUMC EDL monthly meeting October 25,2016 Overview Physiopathology of hypertension Classification

More information

Hypertension in the Era of ACC/AHA: Practice Changing Evidence and Recommendations

Hypertension in the Era of ACC/AHA: Practice Changing Evidence and Recommendations Hypertension in the Era of ACC/AHA: Practice Changing Evidence and Recommendations Gerald W. Smetana, M.D., MACP Division of General Medicine Beth Israel Deaconess Medical Center Professor of Medicine

More information

Hypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute

Hypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated

More information

Osama Sanad (MD) Prof. of Cardiology Benha University 2016

Osama Sanad (MD) Prof. of Cardiology Benha University 2016 Osama Sanad (MD) Prof. of Cardiology Benha University 2016 Back in time. 1912 Back in time. 1912 No body knows that hypertension is a lethal disease Hypertension in 1940s Among anti-hypertensives mentioned

More information

Disclosures. Learning Objectives. Hypertension: a sprint to the finish Ontario Pharmacists Association 1

Disclosures. Learning Objectives. Hypertension: a sprint to the finish Ontario Pharmacists Association 1 Disclosures I have no current or past relationships with commercial entities I have received a speaker s fee from the Ontario Pharmacists Association for this learning activity Laura Tsang PharmD Sunnybrook

More information

Renal Denervation. by Walead Latif, DO, MBA, CPE Assistant Clinical Professor Rutgers Medical School

Renal Denervation. by Walead Latif, DO, MBA, CPE Assistant Clinical Professor Rutgers Medical School Renal Denervation by Walead Latif, DO, MBA, CPE Assistant Clinical Professor Rutgers Medical School Disclosure Information ACOI Annual Meeting I have the following financial relationships to disclose:

More information

Hypertension Management: A Moving Target

Hypertension Management: A Moving Target 9:45 :30am Hypertension Management: A Moving Target SPEAKER Karol Watson, MD, PhD, FACC Presenter Disclosure Information The following relationships exist related to this presentation: Karol E. Watson,

More information

The New Hypertension Guidelines

The New Hypertension Guidelines The New Hypertension Guidelines Joseph Saseen, PharmD Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Disclosure Joseph Saseen reports no conflicts

More information

Is there a mechanism of interaction between hypertension and dyslipidaemia?

Is there a mechanism of interaction between hypertension and dyslipidaemia? Is there a mechanism of interaction between hypertension and dyslipidaemia? Neil R Poulter International Centre for Circulatory Health NHLI, Imperial College London Daegu, Korea April 2005 Observational

More information

Hypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town

Hypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the

More information

Long-Term Care Updates

Long-Term Care Updates Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart

More information

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University

More information

Brent M. Egan, MD Professor of Medicine USCSOM Greenville

Brent M. Egan, MD Professor of Medicine USCSOM Greenville Contemporary Management of Uncontrolled and Treatment Resistant Hypertension Brent M. Egan, MD Professor of Medicine USCSOM Greenville Disclosures (past 3 years): Honoraria: BCBSSC, Medtronic Grant Support:

More information

JNC-8. (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure- 8) An Update on Hypertension Guidelines

JNC-8. (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure- 8) An Update on Hypertension Guidelines JNC-8 (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure- 8) An Update on Hypertension Guidelines Derrick Sorweide, DO Assistant Professor of Family Medicine,

More information

Masked Hypertension. Why Should We Care? Dr. Peter J. Lin Director Primary Care Initiatives - Canadian Heart Research Centre

Masked Hypertension. Why Should We Care? Dr. Peter J. Lin Director Primary Care Initiatives - Canadian Heart Research Centre Masked Hypertension Why Should We Care? Dr. Peter J. Lin Director Primary Care Initiatives - Canadian Heart Research Centre PRESENTER DISCLOSURE Faculty: Dr. Peter Lin Relationships with commercial interests:

More information

Hypertension: Update

Hypertension: Update Hypertension: Update Meenakshi A Bhalla MD,FACC Associate Professor of Medicine Director Preventive Cardiology Advanced Heart Failure and Transplant Cardiology University of Kentucky Faculty Disclosure

More information

Hypertension Guidelines 2017

Hypertension Guidelines 2017 Hypertension Guidelines 2017 (American College of Cardiology and the American Heart Association) In 1977, the 1st comprehensive guideline for detection, evaluation, and management of high BP was published,

More information

Egyptian Hypertension Guidelines

Egyptian Hypertension Guidelines Egyptian Hypertension Guidelines 2014 Egyptian Hypertension Guidelines Dalia R. ElRemissy, MD Lecturer of Cardiovascular Medicine Cairo University Why Egyptian Guidelines? Guidelines developed for rich

More information

Adult Blood Pressure Clinician Guide June 2018

Adult Blood Pressure Clinician Guide June 2018 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Blood Pressure Clinician Guide June 2018 Adult Blood Pressure Clinician Guide June 2018 Introduction This Clinician Guide is based on the 2018

More information

New Hypertension Guideline Recommendations for Adults July 7, :45-9:30am

New Hypertension Guideline Recommendations for Adults July 7, :45-9:30am Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July

More information

Hypertension Controversies: SPRINTing to New Goals

Hypertension Controversies: SPRINTing to New Goals Hypertension Controversies: SPRINTing to New Goals Diana Isaacs, PharmD, BCPS, BC-ADM, CDE Clinical Pharmacy Specialist Cleveland Clinic Lauren Wolfe, PharmD Primary Care Clinical Specialist Cleveland

More information

Int. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences

Int. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences Research Article JNC 8 versus JNC 7 Understanding the Evidences Anns Clara Joseph, Karthik MS, Sivasakthi R, Venkatanarayanan R, Sam Johnson Udaya Chander J* RVS College of Pharmaceutical Sciences, Coimbatore,

More information

Management of Hypertension in Women

Management of Hypertension in Women Management of Hypertension in Women Eliseo J. Pérez-Stable MD Professor of Medicine DGIM, Department of Medicine July 1, 2013 Declaration of full disclosure: No conflict of interest (I have never been

More information

2/9/2017. Financial Disclosures/Unapproved Use. Achieving Harmony in Blood Pressure Guidelines Around the Globe. Roger S. Blumenthal, MD.

2/9/2017. Financial Disclosures/Unapproved Use. Achieving Harmony in Blood Pressure Guidelines Around the Globe. Roger S. Blumenthal, MD. Achieving Harmony in Blood Pressure Guidelines Around the Globe Roger S. Blumenthal, MD The Kenneth Jay Pollin Professor of Cardiology Director, The Johns Hopkins Ciccarone Center for the Prevention Of

More information

Hypertension Pharmacotherapy: A Practical Approach

Hypertension Pharmacotherapy: A Practical Approach Hypertension Pharmacotherapy: A Practical Approach Ronald Victor, MD Burns & Allen Chair in Cardiology Director, The Hypertension Center Associate Director, The Heart Institute Hypertension Center 1. 2.

More information

Treating Hypertension in Individuals with Diabetes

Treating Hypertension in Individuals with Diabetes Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any

More information

Management of Hypertension for Stroke Prevention in New Zealand: Can We Do Better? Walter van der Merwe Nephrologist Waitemata DHB

Management of Hypertension for Stroke Prevention in New Zealand: Can We Do Better? Walter van der Merwe Nephrologist Waitemata DHB Management of Hypertension for Stroke Prevention in New Zealand: Can We Do Better? Walter van der Merwe Nephrologist Waitemata DHB Increasing stroke numbers in New Zealand an 'epidemic' says leading AUT

More information

Hypertension Update Clinical Controversies Regarding Age and Race

Hypertension Update Clinical Controversies Regarding Age and Race Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT

More information

DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE

DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal

More information

Hypertension Update. Aaron J. Friedberg, MD

Hypertension Update. Aaron J. Friedberg, MD Hypertension Update Aaron J. Friedberg, MD Assistant Professor, Clinical Division of General Internal Medicine The Ohio State University Wexner Medical Center Background Diagnosis Management Overview Guideline

More information

Understanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management?

Understanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management? Understanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management? Slides presented during CDMC in Almaty, Kazakhstan on Saturday April 12,

More information

Managing Hypertension in Diabetes Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park.

Managing Hypertension in Diabetes Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park. Managing Hypertension in Diabetes 2015 Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park Case Scenario Mike M is a 59 year old man with type 2 diabetes managed

More information

Hypertension Putting the Guidelines into Practice

Hypertension Putting the Guidelines into Practice Hypertension 2017 Putting the Guidelines into Practice Disclosures Relationships with commercial interests: Grants/Research Support: Speakers Bureau/Honoraria: Consulting Fees: Data Safety and Monitoring:

More information

Management of Hypertension in special groups. DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University

Management of Hypertension in special groups. DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University Management of Hypertension in special groups BY DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University AGENDA SPECIAL GROUPS SPECIFIC DRUDS FOR SPECIAL GROUPS TARGET BP FOR SPECIAL GROUPS:

More information

New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD

New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD None Disclosures Objectives Understand trend in blood pressure clinical practice guidelines

More information

Systolic Blood Pressure Intervention Trial (SPRINT)

Systolic Blood Pressure Intervention Trial (SPRINT) 09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP

More information

Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension

Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Prof. Massimo Volpe, MD, FAHA, FESC, Chair of Cardiology, Department of Clinical and Molecular Medicine

More information

Evolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH)

Evolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH) Evolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH) Sidney C. Smith, Jr. MD, FACC, FAHA, FESC Professor of Medicine/Cardiology University of North Carolina

More information

Hypertension (JNC-8)

Hypertension (JNC-8) Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint

More information

Hypertension Update. Faculty/Presenter Disclosure

Hypertension Update. Faculty/Presenter Disclosure Hypertension Update Who Gives a CHEP About Targets? Faculty/Presenter Disclosure Presenter: Raj Padwal Relationships that may introduce potential bias and/or conflict of interest: Grants/Research Support:

More information

Hypertension Update. Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016

Hypertension Update. Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016 Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016 Hypertension Update Vincent J. Canzanello, M.D. Consultant, Division of Nephrology and Hypertension Professor or Medicine College

More information

Blood Pressure LIMBO How Low To Go?

Blood Pressure LIMBO How Low To Go? Blood Pressure LIMBO How Low To Go? Joseph L. Kummer, MD, FACC Bryan Heart Spring Conference April 21 st, 2018 Hypertension Epidemiology Over a billion people have hypertension Major cause of morbidity

More information

Hypertension Guidelines Michael A. Weber, MD Division of Cardiovascular Medicine State University of New York Downstate Medical Center

Hypertension Guidelines Michael A. Weber, MD Division of Cardiovascular Medicine State University of New York Downstate Medical Center Hypertension Guidelines 2016 Michael A. Weber, MD Division of Cardiovascular Medicine State University of New York Downstate Medical Center Speaker Disclosures I disclose that I am a Consultant for: Ablative

More information

Updates in Cardiovascular Recommendations for Diabetic Patients

Updates in Cardiovascular Recommendations for Diabetic Patients Updates in Cardiovascular Recommendations for Diabetic Patients Chris Tawwater, Pharm.D., BCPS Clinical Pharmacist, Abilene Regional Medical Center Assistant Professor, Adult Medicine Division Pharmacotherapy

More information

Hypertension: JNC-7. Southern California University of Health Sciences Physician Assistant Program

Hypertension: JNC-7. Southern California University of Health Sciences Physician Assistant Program Hypertension: JNC-7 Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! Reference Card

More information